Evidence map›Paper›PMID 41492535›Full record

ArticleMethodsX2025

Hybrid quantum-classical deep learning framework for balanced multiclass diabetic retinopathy classification.

Tabassum Ara, Ved Prakash Mishra, Manish Bali, Anuradha Yenkikar

Abstract read
In one paragraph

Article in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tabassum AraSchool of Engineering, Amity University Dubai Campus, Dubai, 25314, UAE.
Ved Prakash MishraSchool of Engineering, Amity University Dubai Campus, Dubai, 25314, UAE.
Manish BaliSchool of Engineering, Amity University Dubai Campus, Dubai, 25314, UAE.
Anuradha YenkikarSchool of Engineering, Amity University Dubai Campus, Dubai, 25314, UAE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic Retinopathy (DR) is a progressive eye disease and a leading cause of preventable blindness among diabetic patients. Early and accurate classification of its severity stages is crucial for effective treatment but remains challenging due to class imbalance, high-resolution data, and limited scalability of existing models. This study presents a novel hybrid quantum-classical deep learning framework to address these limitations in five-class DR classification. The model achieves a balanced accuracy of 80.96 % on the APTOS 2019 dataset, outperforming several classical baselines across all DR stages. It is optimized for computational efficiency and class-balanced learning, making it suitable for deployment in telemedicine platforms and low-resource clinical settings. This work contributes a scalable AI-based diagnostic approach that fuses deep learning with emerging quantum computing techniques. The methodology, results, and publicly shared codebase provide a replicable framework for researchers and practitioners working in AI for medical imaging and early disease screening. This method is well-suited for low-resource clinical environments and tele-ophthalmology applications. The method involves an:•ResNet-50 feature extractor with a 4-stage dense projection (2048→8) for quantum-ready compression•8-qubit VQC with parameterized RY-RZ gates and ring-style entanglement for high expressiveness•Stratified sampling + mixed-precision training for efficiency and class-balanced generalization.

Indexed as

Diabetic retinopathy detectionMulticlass medical image classificationQuantum machine learning, Hybrid quantum-classical modelResNet50

Identifiers

PMID41492535
PMCPMC12765111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.